About Research Corporation Technologies and Pichia
Research Corporation Technologies (RCT) in Tucson, Ariz., is a technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide.
RCT has played an early role in the commercial success of some of today's important pharmaceuticals, diagnostics and biotechnology products. The company's technology investment and management activities have played a critical role in the commercialization of the blockbuster anticancer drugs cisplatin and carboplatin, the PSA blood test for prostate cancer, technetium-99-based imaging agents, granulocyte-macrophage colony stimulating factor (GM-CSF), nonimmunogenic delivery of protein-based drugs, the fibronectin artificial antibody scaffold, and lacosamide for the treatment of seizures in patients with epilepsy.
RCT's Pichia platform includes Pichia Expression and Pichia GlycoSwitch™. Pichia Expression is used for producing non-glycosylated products, or for products in which yeast glycosylation is acceptable. Pichia GlycoSwitch™ is used for producing human-like glycosylated products.
Through a partnership with Invitrogen Corporation, RCT offers kits that contain the Pichia Expression materials to researchers worldwide. The purchase of a kit from Invitrogen allows the user to evaluate Pichia for up to one year. If the user wishes to continue using Pichia Expression, RCT offers flexible nonexclusive licenses for commercial use and sales, and licenses for commercial research and in-house development. These licenses have various fees and royalty rates tailored to different business plans, such as pharmaceuticals, diagnostics, industrial enzymes, animal health products and reagents.
More information about Pichia GlycoSwitch™ can be obtained by contacting RCT.
Today, Pichia is one of the standard technologies in use for recombinant protein production and is especially useful for large scale fermentation. RCT has licensed Pichia Expression to more than 120 companies in the biotechnology, pharmaceutical, animal health and food industries.
